Bosentan for chronic thromboembolic pulmonary hypertension

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 12, 2009, Pages 1503-1512

  Confalonieri, Marco ^a   Kodric, Metka ^a   Longo, Cinzia ^a   Vassallo, Fabio G ^a  

^a UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

Author keywords

Bosentan; Chronic thromboembolism; Endothelin 1; Pulmonary arterial hypertension; Pulmonary endarterectomy

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BOSENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ILOPROST; PLACEBO; PROSTACYCLIN; SILDENAFIL; UNIPROST; WARFARIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANKLE EDEMA; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CLINICAL TRIAL; DISTRIBUTION VOLUME; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; ENDARTERECTOMY; EXERCISE TOLERANCE; FUNCTIONAL STATUS; HALF LIFE TIME; HEART PALPITATION; HEART RIGHT VENTRICLE FAILURE; HEMOGLOBIN DETERMINATION; HUMAN; LIVER FUNCTION TEST; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MAXIMUM PLASMA CONCENTRATION; OVERALL SURVIVAL; PERIPHERAL EDEMA; PLASMA PROTEIN BINDING; POSTMARKETING SURVEILLANCE; PULMONARY HYPERTENSION; RESPIRATORY TRACT INFECTION; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SURGICAL MORTALITY; SURVIVAL RATE; VERTIGO;

ANTIHYPERTENSIVE AGENTS; CHRONIC DISEASE; HUMANS; HYPERTENSION, PULMONARY; RECEPTORS, ENDOTHELIN; SULFONAMIDES; THROMBOEMBOLISM;

EID: 73349089033     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.148     Document Type: Review

References (60)

1. ▶1 Fedullo PF, Auger WR, Kerr KM et al. Chronic thromboembolic pulmonary hypertension. N. Engl. J. Med. 345, 1465-1472 (2001).
2. ▶2 Deng Z, Morse JH, Slager SL et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am. J. Hum. Genet. 67, 737-744 (2000).
3. ▶3 Thomson JR, Machado RD, Pauciulo MW et al. Sporadic primary pulmonary hypertension is associated with germ line mutations of the gene encoding BMPR-II, a receptor member of the TGF-b family. J. Med. Genet. 37, 741-745 (2000).
4. Lang IM, Bonderman D, Jakowitsch J et al. Chronic thromboembolic pulmonary hypertension: update 2004. Eur. Respir. Mon. 27, 243-252 (2003).
5. ▶5 Peacock AJ. Primary pulmonary hypertension. Thorax 54, 1107-1118 (1999).
6. ▶6 D'Alonzo GE, Bower JS, Dantzker DR. Differentiation of patients with primary and thromboembolic pulmonary hypertension. Chest 85, 457-461 (1984). • First paper systematically comparing chronic thromboembolic pulmonary hypertension (CTEPH) with idiopathic pulmonary arterial hypertension (PAH).
7. Bonderman D, Wilkens H, Wakounig S et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur. Respir. J. 33, 325-331 (2009). • Comprehensive review of all the demonstrated risk factors for CTEPH.
8. ▶8 Fedullo PF, Kerr KM, Auger WR et al. Chronic thromboembolic pulmonary hypertension. Semin. Respir. Crit. Care Med. 21, 563-574 (2000).
9. ▶9 Egermayer P, Peacock AJ. Is pulmonary embolism a common cause of chronic pulmonary hypertension? Limitations of the embolic hypothesis. Eur. Respir. J.15, 440-448 (2000).
10. ▶10 Fedullo PF, Rubin LJ, Kerr KM et al. The natural history of acute and chronic thromboembolic disease: the searching for the missing link. Eur. Respir. J. 15, 435-437(2000).
11. ▶11 Lang IM. Chronic thromboembolic pulmonary hypertension: not so rare after all. N. Engl. J. Med. 350, 2236-2238 (2004).
12. ▶12 Pengo V, Lensing AW, Prins MH et al.; Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N. Engl. J. Med. 350, 2257-2264 (2004). • Largest epidemiological survey on the incidence of CTEPH after acute pulmonary embolism.
13. ▶13 Becattini C, Agnelli G, Pesavento R et al. Incidence of chronic thromboembolic pulmonary hypertension after a first episod of pulmonary embolism. Chest 103, 172-175 (2006).
14. ▶14 Tapson VF, Humbert M. Incidence and prevalence of chronic thromboembolic pulmonary hypertension. From acute to chronic pulmonary embolism. Proc. Am. Thor. Soc. 3, 564-567 (2006).
15. ▶15 Simonneau G, Robbins IM, Beghetti M et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 29, S43-S54 (2009). • Most updated classification of PAH by the 4th World Symposium on PAH held in Dana Point, CA, USA, 2008.
16. ▶16 Riedel M, Stanek V, Widimsky J, Prerovsky I. Long-term follow-up of patients with pulmonary thromboembolism: late prognosis and evolution of hemodynamic and respiratory data. Chest 81,151-158 (1982).
17. ▶17 Ribeiro A, Lindmarker P, Johnsson H et al. Pulmonary embolism: one-year follow-up with echocardiography Doppler and five-year survival analysis. Circulation 99, 1325-1330 (1999).
18. ▶18 Rubens FD, Bourke M, Hynes M et al. Surgery for chronic thromboembolic pulmonary hypertension: inclusive experience from a national referral center. Ann. Thorac. Surg. 83, 1075-1081 (2007).
19. ▶19 Jamieson SW, Kapelanski DP, Sakakibara N et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann. Thorac. Surg. 76,1457-1464 (2003). • Impressive case series of surgically treated CTEPH patients from the world's most experienced center for pulmonary endoarterectomy.
20. ▶20 Thistlethwaite PA Madani M, Jamieson SW. Outcomes of pulmonary endarterectomy surgery. Semin. Thorac. Cardiovasc. Surg. 18, 257-264 (2003).
21. D'Armini AM, Zanotti G, Pozzi M et al. Surgical treatment of chronic thromboembolic pulmonary hypertension with pulmonary endarterectomy. G. Ital. Cardiol. 7(7), 454-463 (2006).
22. ▶22 Lewkzuc J, Pizsko P, Jagas J et al. Prognostic factors in medically treated patients with chronic pulmonary embolism. Chest 119 (3), 818-823 (2001).
23. ▶23 Ribeiro A, Lindmarker P, Johnsson H et al. Pulmonary embolism: one-year follow-up with echocardiography Doppler and five-year survival analysis. Circulation 99, 1325-1330 (1999).
24. ▶24 Dingemanse J, van Giersbergen PL. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin. Pharmacokinet. 43 (15), 1089-1115 (2004). • Documented review on the pharmacologic properties of bosentan.
25. ▶25 Dingemanse J, van Giersbergen PL, Weidekamm E et al. Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin antagonist. J. Clin. Pharmacol. 42(3), 283-289 (2002).
26. ▶26 Dingemanse J, van Giersbergen PL. Influence of severe renal dysfunction on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. Int. J. Clin. Pharmacol. Ther. 40 (7), 310-316 (2002).
27. ▶27 Goto K. Basic and therapeutic relevance of endothelin-mediated regulation. Biol. Pharm. Bull. 24, 1219-1230 (2001).
28. ▶28 Giaid A, Yanagisawa M, Langleben D et al. Expression of endothelin- 1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 328,1732-1739 (1993).
29. ▶29 Rubens C, Ewert R, Halank M et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 120, 1562-1569 (2001).
30. ▶30 Reesink HJ, Meijer RC, Lutter R et al. Hemodynamic and clinical correlates of endothelin-1 in chronic thromboembolic pulmonary hypertension. Circ. J. 70, 1058-1063 (2006).
31. ▶31 Kim H, Yung GL, Marsh JJ et al. Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. Eur. Respir. J. 15, 640-648 (2000). • Experimental basis for the role of endothelin-1 in CTEPH.
32. ▶32 Bonderman D, Nowotny R, Skoro-Sajer N et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 128, 2599-2603 (2005). • Preliminary open-label study on limited CTEPH patient population.
33. ▶33 Hoeper MM, Kramm T, Wilkens H et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 128, 2363-2367 (2005). • Preliminary open-label study recruiting few CTEPH patients for a very short period of therapy with bosentan showing favorable results.
34. ▶34 Hughes R, George P, Parameshwar J et al. Bosentan in inoperable chronic thromboembolic pulmonary hypertension. Thorax 60, 707 (2005).
35. ▶35 Hughes RJ, Jais X, Bonderman D et al. Bosentan in inoperable chronic thromboembolic pulmonary hypertension: efficacy at 1 year. Eur. Respir. J. 28, 138-143 (2006). • Reports the efficacy and safety of compassionate use of bosentan in patients with inoperable CTEPH after at least 1 year of therapy.
36. ▶36 Seyfarth HJ, Hammerschmidt S, Pankau H et al. Long-term bosentan in chronic thromboembolic pulmonary hypertension. Respiration 74, 287-292 (2007).
37. ▶37 Segovia Cubero J, Ortiz Uribe JC, Gómez Bueno M et al. Role of bosentan in patients with chronic venous thromboembolic pulmonary hypertension. Med. Clin. 128, 12-14 (2007).
38. ▶38 Ulrich S, Speich R, Domenighetti G et al. Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of bosentan on hemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study). Swiss Med. Wkly 137, 573-580 (2007). • Open-label national study to evaluate the effects of bosentan on hemodynamics, exercise capacity, quality of life, safety and tolerability in patients with CTEPH.
39. ▶39 Condliffe R, Kiely DG, Gibbs JSR et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am. J. Respir. Crit. Care Med. 177, 1122-1127 (2008). • Interesting real-life study showing survival benefits of bosentan and other anti-PAH agents in patients with CTEPH who were inoperable or showed persistent PAH after pulmonary endarterectomy (PEA).
40. ▶40 Vassallo FG, Kodric M, Scarduelli C et al. Bosentan for patients with chronic thromboembolic pulmonary hypertension. Eur. J. Intern. Med. 20, 24-29 (2009). • A 1-year, multicenter, open-label, controlled trial on bosentan in CTEPH.
41. ▶41 Reesink HJ, Sulaiman S, Kloek JJ et al. Bosentan as a bridge to pulmonary endoarterectomy for thromboembolic pulmonary hypertension. J. Thorac. Cardiovasc. Surg. DOI:10.1016/j. jtcvs.2009.03.053 (2009) (Epub ahead of print). • Study of bosentan as bridge medical therapy before PEA with encouraging results.
42. ▶42 Jaïs X, D'Armini AM, Jansa P et al. Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension Study Group. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension), a randomized, placebocontrolled trial. J. Am. Coll. Cardiol. 52, 2127-2134 (2008). • Only rigorously conducted trial of any drug with the specific indication of CTEPH.
43. ▶43 Channick RN, Sitbon O, Barst RJ et al. Endothelin receptor antagonist in pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43, S62-S67 (2004).
44. ▶44 Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346, 896-903 (2002).
45. ▶45 McLaughin VV, Hoeper MM. Pulmonary Arterial hypertension - the race for the most effective treatment. Am. J. Respir. Crit. Care Med. 171, 1199-1201 (2005).
46. ▶46 Spence S, Anderson C, Cukierski M et al. Teratogenic effects of the endothelin receptor antagonist L-753, 037 in the rat. Reprod. Toxicol. 13, 15-29 (1999). • Experimental basis that led to avoidance of bosentan use during pregnancy.
47. Weber C, Banken L, Birnboeck H, Schulz R. Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. J. Clin. Pharmacol. 139, 847-854 (1999).
48. ▶48 Murphey LM, Hood EH. Bosentan and warfarin interaction. Ann. Pharmacother. 37, 1028-1031 (2003).
49. ▶49 Paul GA, Gibbs JS, Boobis AR et al. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br. J. Clin. Pharmacol. 60, 107-112 (2005).
50. ▶50 Humbert M, Segal ES, Kiely DG et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur. Respir. J. 30(2), 338-344 (2007). • Internet-based post-marketing surveillance survey; interesting source of clinical information and an example that should also be followed by the next generation of drugs.
51. Carlsen J, Hoeper MM, Kiely DG et al. Long-term safety profile of bosentan in patients with chronic thromboembolic pulmonary hypertension (CTEPH): results from the TRAX database. Presented at: Annual Meeting of the European Society of Cardiology (ESC). Stockholm, Denmark, 3-7 September 2005 (abstract 763).
52. ▶52 Suntharalingham J, Hodgkins D, Cafferty FH et al. Does rapid dose titration affect the hepatic safety profile of bosentan? Vasc. Pharmacol. 44, 508-512 (2006).
53. ▶53 Beghetti M. Bosentan in pediatric patients with pulmonary arterial hypertension. Curr. Vasc. Pharmacol. 7(2), 225-233 (2009).
54. ▶54 Keogh AM, McNeil KD, Wlodarczyk J et al. Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan. J. Heart Lung Transplant. 26(2), 181-187 (2007).
55. ▶55 Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest 103, 685-692 (1993).
56. ▶56 Yi ES, Kim H, Ahn H, Strother J et al. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension: a morphometric and immunohistochemical study. Am. J. Respir. Crit. Care Med. 162, 1577-1586 (2000).
57. ▶57 Dartevelle P, Fadel E, Mussot S et al. Chronic thromboembolic pulmonary hypertension. Eur. Respir. J. 23, 637- 648 (2004).
58. ▶58 Peacock AJ, Naeije R, Galiè N, Rubin LJ. End-points and clinical trial design in pulmonary arterial hypertension: have we made progress? Eur. Respir. J. 34, 231-242 (2009). • Critical revision of the usual and less common clinical end points for clinical trials in PAH.
59. ▶59 Bresser P, Pepke-Zaba J, Jais X et al. Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm. Proc. Am. Thor. Soc. 3, 594-600 (2006).
60. Nainggolan L. Hope at last? Bosentan for inoperable PAH. Heartwire News 30December 2008 www.theheart.org/article/931295.do (Accessed 20 July 2009)